Clinical Trial Update: Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids [Phase 4]

View source ↗

Summary

Clinical Trial Update on escalating doses of incobotulinumtoxinA (Xeomin) for treating glabellar lines in a Phase 4 study; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Elastosis Senilis
• Skin Aging

Drugs mentioned

• XEOMIN (INCOBOTULINUMTOXINA)

Snippet

Sponsor: The Maas Clinic | Conditions: Skin Aging, Elastosis Senilis | Phase 4 | Status: UNKNOWN